🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14 results for “IDEAYA Biosciences” Clear

  1. DACARBAZINE, IPILIMUMAB, IDE196 (LXS196), NIVOLUMAB, CRIZOTINIB, CRIZOTINIB, PEMBROLIZUMAB, IDE196 (LXS196)

    IDEAYA Biosciences

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  2. DACARBAZINE, PEMBROLIZUMAB, IDE196 (LXS196), CRIZOTINIB, IPILIMUMAB, NIVOLUMAB, CRIZOTINIB, IDE196 (LXS196)

    IDEAYA Biosciences

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  3. Darovasertib

    IDEAYA Biosciences

    Uveal Melanoma

    phase 3 small molecule active

    2 trials

  4. IDE196

    IDEAYA Biosciences

    Metastatic Uveal Melanoma

    phase 3 small molecule active

    2 trials

  5. IDE196 (LXS196), IDE196 (LXS196)

    IDEAYA Biosciences

    Uveal Melanoma

    phase 3 small molecule active

    1 trial

  6. GSK4418959

    IDEAYA Biosciences

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  7. IDE574

    IDEAYA Biosciences

    ER+, HER 2- Breast Cancer

    phase 2 small molecule active

    1 trial

  8. IDE849

    IDEAYA Biosciences

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. NORETHISTERONE AND ETHINYLESTRADIOL , IDE196 (LXS196), IDE196 (LXS196), METFORMIN HYDROCHLORIDE

    IDEAYA Biosciences

    Uveal Melanoma

    phase 2 small molecule active

    1 trial

  10. An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors.

    IDEAYA Biosciences

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  11. IDE-161

    IDEAYA Biosciences

    Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  12. IDE034

    IDEAYA Biosciences

    Esophageal Squamous Cell Carcinoma

    phase 1 small molecule active

    1 trial

  13. IDE397

    IDEAYA Biosciences

    Solid Tumor

    phase 1 small molecule active

    1 trial

  14. IDE892

    IDEAYA Biosciences

    NSCLC Adenocarcinoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources